These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 18441313

  • 1. Comparison of bevacizumab, ranibizumab, and pegaptanib in vitro: efficiency and possible additional pathways.
    Klettner A, Roider J.
    Invest Ophthalmol Vis Sci; 2008 Oct; 49(10):4523-7. PubMed ID: 18441313
    [Abstract] [Full Text] [Related]

  • 2. Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells.
    Spitzer MS, Yoeruek E, Sierra A, Wallenfels-Thilo B, Schraermeyer U, Spitzer B, Bartz-Schmidt KU, Szurman P.
    Graefes Arch Clin Exp Ophthalmol; 2007 Dec; 245(12):1837-42. PubMed ID: 17347807
    [Abstract] [Full Text] [Related]

  • 3. Comparison of the efficacy of aflibercept, ranibizumab, and bevacizumab in an RPE/choroid organ culture.
    Klettner A, Recber M, Roider J.
    Graefes Arch Clin Exp Ophthalmol; 2014 Oct; 252(10):1593-8. PubMed ID: 25047874
    [Abstract] [Full Text] [Related]

  • 4. Toxicity testing of the VEGF inhibitors bevacizumab, ranibizumab and pegaptanib in rats both with and without prior retinal ganglion cell damage.
    Thaler S, Fiedorowicz M, Choragiewicz TJ, Bolz S, Tura A, Henke-Fahle S, Yoeruek E, Zrenner E, Bartz-Schmidt KU, Ziemssen F, Schuettauf F.
    Acta Ophthalmol; 2010 Aug; 88(5):e170-6. PubMed ID: 20491691
    [Abstract] [Full Text] [Related]

  • 5. Different properties of VEGF-antagonists: Bevacizumab but not Ranibizumab accumulates in RPE cells.
    Klettner AK, Kruse ML, Meyer T, Wesch D, Kabelitz D, Roider J.
    Graefes Arch Clin Exp Ophthalmol; 2009 Dec; 247(12):1601-8. PubMed ID: 19597740
    [Abstract] [Full Text] [Related]

  • 6. Comparison of choroidal and retinal endothelial cells: characteristics and response to VEGF isoforms and anti-VEGF treatments.
    Stewart EA, Samaranayake GJ, Browning AC, Hopkinson A, Amoaku WM.
    Exp Eye Res; 2011 Nov; 93(5):761-6. PubMed ID: 21970900
    [Abstract] [Full Text] [Related]

  • 7. [VEGF in age-related macular degeneration. Part II. VEGF inhibitors use in age-related macular degeneration treatment].
    Wylegała E, Teper SJ.
    Klin Oczna; 2007 Nov; 109(1-3):97-100. PubMed ID: 17687925
    [Abstract] [Full Text] [Related]

  • 8. Long-term treatment with anti-VEGF does not induce cell aging in primary retinal pigment epithelium.
    Schottler J, Randoll N, Lucius R, Caliebe A, Roider J, Klettner A.
    Exp Eye Res; 2018 Jun; 171():1-11. PubMed ID: 29522724
    [Abstract] [Full Text] [Related]

  • 9. Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells.
    Spitzer MS, Wallenfels-Thilo B, Sierra A, Yoeruek E, Peters S, Henke-Fahle S, Bartz-Schmidt KU, Szurman P, Tuebingen Bevacizumab Study Group.
    Br J Ophthalmol; 2006 Oct; 90(10):1316-21. PubMed ID: 16723358
    [Abstract] [Full Text] [Related]

  • 10. VEGF antagonists decrease barrier function of retinal pigment epithelium in vitro: possible participation of intracellular glutathione.
    Miura Y, Klettner A, Roider J.
    Invest Ophthalmol Vis Sci; 2010 Sep; 51(9):4848-55. PubMed ID: 20435596
    [Abstract] [Full Text] [Related]

  • 11. Vascular Endothelial Growth Factor (VEGF) Concentration Is Underestimated by Enzyme-Linked Immunosorbent Assay in the Presence of Anti-VEGF Drugs.
    Takahashi H, Nomura Y, Nishida J, Fujino Y, Yanagi Y, Kawashima H.
    Invest Ophthalmol Vis Sci; 2016 Feb; 57(2):462-6. PubMed ID: 26868748
    [Abstract] [Full Text] [Related]

  • 12. Retinal function and morphology in rabbit after intravitreal injection of VEGF inhibitors.
    Myers AC, Lövestam Adrian M, Bruun A, Ghosh F, Andréasson S, Ponjavic V.
    Curr Eye Res; 2012 May; 37(5):399-407. PubMed ID: 22510009
    [Abstract] [Full Text] [Related]

  • 13. Influence of non-toxic doses of bevacizumab and ranibizumab on endothelial functions and inhibition of angiogenesis.
    Barzelay A, Lowenstein A, George J, Barak A.
    Curr Eye Res; 2010 Sep; 35(9):835-41. PubMed ID: 20795866
    [Abstract] [Full Text] [Related]

  • 14. Aflibercept, bevacizumab and ranibizumab prevent glucose-induced damage in human retinal pericytes in vitro, through a PLA2/COX-2/VEGF-A pathway.
    Giurdanella G, Anfuso CD, Olivieri M, Lupo G, Caporarello N, Eandi CM, Drago F, Bucolo C, Salomone S.
    Biochem Pharmacol; 2015 Aug 01; 96(3):278-87. PubMed ID: 26056075
    [Abstract] [Full Text] [Related]

  • 15. Penetration of bevacizumab and ranibizumab through retinal pigment epithelial layer in vitro.
    Terasaki H, Sakamoto T, Shirasawa M, Yoshihara N, Otsuka H, Sonoda S, Hisatomi T, Ishibashi T.
    Retina; 2015 May 01; 35(5):1007-15. PubMed ID: 25627091
    [Abstract] [Full Text] [Related]

  • 16. Comparative effects of bevacizumab, ranibizumab and pegaptanib at intravitreal dose range on endothelial cells.
    Carneiro A, Falcão M, Pirraco A, Milheiro-Oliveira P, Falcão-Reis F, Soares R.
    Exp Eye Res; 2009 Mar 01; 88(3):522-7. PubMed ID: 19135441
    [Abstract] [Full Text] [Related]

  • 17. Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab.
    Meyer CH, Holz FG.
    Eye (Lond); 2011 Jun 01; 25(6):661-72. PubMed ID: 21455242
    [Abstract] [Full Text] [Related]

  • 18. Compatibility of recombinant tissue plasminogen activator (rtPA) and aflibercept or ranibizumab coapplied for neovascular age-related macular degeneration with submacular haemorrhage.
    Klettner A, Grotelüschen S, Treumer F, Roider J, Hillenkamp J.
    Br J Ophthalmol; 2015 Jun 01; 99(6):864-9. PubMed ID: 25740806
    [Abstract] [Full Text] [Related]

  • 19. Actions of bevacizumab and ranibizumab on microvascular retinal endothelial cells: similarities and differences.
    Deissler HL, Deissler H, Lang GE.
    Br J Ophthalmol; 2012 Jul 01; 96(7):1023-8. PubMed ID: 22539748
    [Abstract] [Full Text] [Related]

  • 20. Effects of bevacizumab (Avastin) on retinal cells in organotypic culture.
    Kaempf S, Johnen S, Salz AK, Weinberger A, Walter P, Thumann G.
    Invest Ophthalmol Vis Sci; 2008 Jul 01; 49(7):3164-71. PubMed ID: 18344448
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.